In addition to pricing the biggest biotech IPO of the week, Braveheart Bio’s underwriters exercised their option to purchase more shares, boosting the clinical-stage company’s total haul to nearly $440 million. Braveheart’s lead drug could be competitive with a blockbuster Bristol Myers Squibb medicine for a type of cardiomyopathy. The post Braveheart Bio’s $382M IPO for Heart Drug Leads a Big Week for Biotech IPOs appeared first on MedCity News.

In this episode, we’re joined by Cheryl Larson, president and CEO of the Midwest Business Group on Health, for our first in-person recording at MedCity News’ recent Bullseye event. The post MedCity FemFwd: Employer Strategies for Women’s Health appeared first on MedCity News.

Hinge Health’s acquisition of Cylinder expands it into GI care, but experts differ on whether employers will favor convenience or specialized solutions. The post Two Differing POVs Emerge About the Hinge-Cylinder Deal appeared first on MedCity News.

Latigo Biotherapeutics will apply the IPO proceeds toward a pipeline that includes a next-generation non-opioid pain drug ready for pivotal testing. BlossomHill Therapeutics also debuted on the Nasdaq, raising cash for cancer drugs designed to address mutations not covered by currently available therapies. The post Latigo Bio’s IPO Lands $346M for Pipeline of Non-Opioid Pain Drugs appeared first on MedCity News.

The problem may not be the investment. It may be the target of the intervention. The post Why Kidney Care’s Biggest Investment Wave Hasn’t Moved Hospital Costs appeared first on MedCity News.

A letter to Medicaid Directors, State Leaders, and other invested collaborators who were awarded Rural Health Transformation (RHT) Grant funding. The post My Wish For Better Care For Americans Living in Rural Areas appeared first on MedCity News.

A bipartisan group of six senators introduced a bill to reform the 340B drug program, locking in hospitals’ use of contract pharmacies and adding new transparency and compliance rules. The legislation would also kill HHS’ contested rebate pilot within a year and replace it with a national data clearinghouse to catch duplicate discounts. The post Bipartisan Lawmakers Are Fighting HHS’ 340B Rebate Push appeared first on MedCity News.

Replimune went from an FDA rejection to a resubmission, a positive advisory committee vote, and finally an accelerated regulatory approval for advanced melanoma — all in less than four months. The FDA nod for Replimune’s oncolytic viral therapy, Tudriqev, positions it as a more convenient alternative to an Iovance Biotherapeutics cell therapy that had been the only treatment in this setting. The post Recovery for Replimune: Accelerated Approval for Cancer Drug Twice Spurned by FDA appeared first on MedCity News.

Democratic senators are urging CMS to withdraw its Medicaid work requirements rule, arguing it will create administrative burdens and cause eligible beneficiaries to lose coverage. The post Democratic Senators Urge Withdrawal of Interim Final Rule on Medicaid Work Requirements appeared first on MedCity News.

Historically, prevention has focused on protecting teeth from decay and gum disease. However, long-term oral health is also shaped by how the teeth, muscles, and jaw function together over time. The post The Missing Piece of Preventive Dental Care Lies in the Bite appeared first on MedCity News.

Gaps in prevention are not frequently due to a complete lack of information, but instead the fact that organizations don’t have a clear way to see how the pieces fit together until after an incident has occurred. The post Healthcare Workplace Violence Prevention Needs Better Visibility Into Risk Signals appeared first on MedCity News.

Scheduled for October 29 at Pegasus Park in Dallas, the theme of the INVEST Digital Health conference will be consumers in healthcare from d2c diagnostics to GLP-1 drugs and wearables. Register today! The post INVEST Digital Health Conference Returns with Focus on Consumers appeared first on MedCity News.

The FDA approved Moderna’s flu vaccine mFLUSIVA, a regulatory decision that comes six months after the agency refused to review the mRNA shot and then quickly reversed its position. But a recommendation from a Centers for Disease Control and Prevention advisory committee is key for payer coverage, and that committee has not met all year due to ongoing litigation. The post Moderna Gets FDA Approval for mRNA Flu Vaccine, But CDC Input Still Uncertain appeared first on MedCity News.

A new survey found that many employers are considering ICHRAs, though concerns about awareness, affordability and the individual insurance market continue to slow adoption. The post Report: What Employers Think About ICHRAs appeared first on MedCity News.

At MedCity News’ inaugural Bullseye conference in Chicago, Debunked Podcast co-hosts Arundhati Parmar and Samir Batra discussed recent CMS actions and Mayo Clinic’s former research director, who has filed a complaint against the medical center over how it’s deploying AI. The post Debunked Episode 29: CMS GLP-1 Drug Pilot Program, RPM Strategy Raise Questions appeared first on MedCity News.